All patients
Age < 65y (younger) ECOG 0 ECOG 1 Gender, male P16 negative (HPV) P16 positive (HPV) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic-recurrent HNSCC (mHNSCC), nivolumab alone vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 141, 2016 0.70 [0.51; 0.96]
0.70 [0.51 ; 0.96 ] CheckMate 141, 2016 1 0% 361 NA not evaluable deaths (OS) (extension)detailed results CheckMate 141, 2016 0.68 [0.54; 0.86]
0.68 [0.54 ; 0.86 ] CheckMate 141, 2016 1 0% 361 NA not evaluable PFS (extension)detailed results CheckMate 141, 2016 0.87 [0.68; 1.11]
0.87 [0.68 ; 1.11 ] CheckMate 141, 2016 1 0% 361 NA not evaluable progression or deaths (PFS)detailed results CheckMate 141, 2016 0.89 [0.70; 1.13]
0.89 [0.70 ; 1.13 ] CheckMate 141, 2016 1 0% 361 NA not evaluable objective responses (ORR)detailed results CheckMate 141, 2016 2.51 [1.07; 5.86]
2.51 [1.07 ; 5.86 ] CheckMate 141, 2016 1 0% 361 NA not evaluable objective responses (ORR) (extension)detailed results CheckMate 141, 2016 2.51 [1.07; 5.86]
2.51 [1.07 ; 5.86 ] CheckMate 141, 2016 1 0% 361 NA not evaluable TRAE (any grade)detailed results CheckMate 141, 2016 0.31 [0.18; 0.52]
0.31 [0.18 ; 0.52 ] CheckMate 141, 2016 1 0% 347 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 141, 2016 0.94 [0.08; 10.48]
0.94 [0.08 ; 10.48 ] CheckMate 141, 2016 1 0% 347 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 141, 2016 0.45 [0.18; 1.11]
0.45 [0.18 ; 1.11 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
0.23 [0.01 ; 7.01 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.94 [0.03; 28.25]
0.94 [0.03 ; 28.25 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.06; 0.92]
0.23 [0.06 ; 0.92 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.02; 2.59]
0.23 [0.02 ; 2.59 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.12 [0.01; 2.59]
0.12 [0.01 ; 2.59 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 0.94 [0.03; 28.25]
0.94 [0.03 ; 28.25 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
0.23 [0.01 ; 7.01 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.78 [0.18; 3.32]
0.78 [0.18 ; 3.32 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 0.23 [0.02; 2.59]
0.23 [0.02 ; 2.59 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 0.94 [0.08; 10.48]
0.94 [0.08 ; 10.48 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
0.23 [0.01 ; 7.01 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.94 [0.03; 28.25]
0.94 [0.03 ; 28.25 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.03; 7.55]
0.47 [0.03 ; 7.55 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 141, 2016 3.81 [0.20; 72.71]
3.81 [0.20 ; 72.71 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
0.23 [0.01 ; 7.01 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.08 [0.00; 1.54]
0.08 [0.00 ; 1.54 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
0.23 [0.01 ; 7.01 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
0.23 [0.01 ; 7.01 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 141, 2016 1.89 [0.08; 42.24]
1.89 [0.08 ; 42.24 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.12 [0.01; 2.59]
0.12 [0.01 ; 2.59 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 1.89 [0.08; 42.24]
1.89 [0.08 ; 42.24 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 0.12 [0.01; 2.59]
0.12 [0.01 ; 2.59 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Skin exfoliation TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.12 [0.01; 2.59]
0.12 [0.01 ; 2.59 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Urticaria TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Rash AE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
0.23 [0.01 ; 7.01 ] CheckMate 141, 2016 1 0% 347 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-01 13:47 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 276,103,277,102,109,278,101,192,114
- treatments: 360,719,721,720
